Investigational drug · Phase 3
CMAB015
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Psoriasis.
Phase 3Last checked: Nov 19, 2026Latest source record: May 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "CMAB015"
First trial start
2024
Aug 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CMAB015", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriasis
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "CMAB015" as an intervention, largest first.
- Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Taizhou Mabtech Pharmaceutical Co.,LtdIndustry
NCT06398652 · 336 participants · Start Aug 27, 2024 · Primary completion Jun 30, 2025
Drug: CMAB015; Secukinumab · For: Psoriasis
Sites: Shanghai, China
- Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy VolunteersPivotal-lookingCompleted
Taizhou Mabtech Pharmaceutical Co.,LtdIndustry
NCT05734482 · 130 participants · Start Feb 15, 2023 · Primary completion Jul 3, 2023
Drug: Secukinumab · For: Psoriasis
Sites: Hefei, China
- Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy VolunteersPivotal-lookingCompleted
Taizhou Mabtech Pharmaceutical Co.,LtdIndustry
NCT07254325 · 114 participants · Start Dec 15, 2025 · Primary completion Jun 12, 2026
Drug: Secukinumab 150mg s.c. · For: Psoriasis
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
Also in development for Psoriasis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- AK111Phase 32 trials
Akeso · Psoriasis, Skin Diseases, Ankylosing Spondylitis
- IBI112Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriasis
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- HPP737Phase 31 trial
Newsoara Biopharma Co., Ltd. · Psoriasis
- LZM012Phase 31 trial
Livzon Pharmaceutical Group Inc. · Psoriasis
- Open-Label EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.